AUTL - Autolus Therapeutics PLC Stock Price, Fair Value and News

$2.29+0.05 (+2.23%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AUTL Price Action

Last 7 days

-8.0%

Last 30 days

-18.2%

Last 90 days

-38.6%

Trailing 12 Months

-59.4%

AUTL RSI Chart

AUTL Valuation

Market Cap

609.4M

Price/Earnings (Trailing)

-2.26

Price/Sales (Trailing)

772.61

EV/EBITDA

0.24

Price/Free Cashflow

-2.96

AUTL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AUTL Fundamentals

AUTL Revenue

Revenue (TTM)

1.2M

AUTL Earnings

Earnings (TTM)

-270.2M

Earnings Growth (Yr)

-79.05%

Earnings Growth (Qtr)

-40.88%

AUTL Profitability

EBT Margin

-21835.69%

Return on Equity

-56.66%

Return on Assets

-32.66%

Free Cashflow Yield

-33.74%

AUTL Investor Care

Shares Dilution (1Y)

52.95%

Diluted EPS (TTM)

-1.22

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	1.2M	0	0	0
2020	1.3M	1.2M	0	0
2019	3.0M	2.9M	2.9M	2.9M
2018	0	1.5M	1.4M	1.3M
2017	0	0	1.7M	1.6M
2016	0	0	1.2M	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Autolus Therapeutics PLC

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

CEO	Dr. Christian Martin Itin Ph.D.
WEBSITE	autolus.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	399

Autolus Therapeutics PLC Frequently Asked Questions

What is the ticker symbol for Autolus Therapeutics PLC? What does AUTL stand for in stocks?

AUTL is the stock ticker symbol of Autolus Therapeutics PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Autolus Therapeutics PLC (AUTL)?

As of Fri Dec 20 2024, market cap of Autolus Therapeutics PLC is 609.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AUTL stock?

You can check AUTL's fair value in chart for subscribers.

Is Autolus Therapeutics PLC a good stock to buy?

The fair value guage provides a quick view whether AUTL is over valued or under valued. Whether Autolus Therapeutics PLC is cheap or expensive depends on the assumptions which impact Autolus Therapeutics PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AUTL.

What is Autolus Therapeutics PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, AUTL's PE ratio (Price to Earnings) is -2.26 and Price to Sales (PS) ratio is 772.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AUTL PE ratio will change depending on the future growth rate expectations of investors.